Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Jisheng Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4550-4897; OpenAlex author ID A5101534899, A5101534902. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 12

  1. Tumour-infiltrating adipocyte-derived 12,13-DiHOME subverts CD8+ T cell immunity in pancreatic ductal adenocarcinoma by promoting PPARγ-mediated ferritinophagy… Co-author DOI 10.1136/gutjnl-2025-337119↗
  2. Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Format… Co-author DOI 10.1158/0008-5472.can-25-2854↗
  3. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  4. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  5. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04693-4↗
  6. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  7. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.655152↗
  8. Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2'-Deoxycytidine Against Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.00612↗
  9. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-019-1278-9↗
  10. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  11. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗
  12. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Co-author DOI 10.18632/oncotarget.18669↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rui Kong · 9 shared papers, 2017–2026 · strength 1.21
  2. Guanqun Li · 7 shared papers, 2018–2026 · strength 1.09
  3. Hongze Chen · 8 shared papers, 2018–2023 · strength 0.93
  4. Yongwei Wang · 7 shared papers, 2017–2026 · strength 0.90
  5. Zhongjie Zhao · 6 shared papers, 2019–2023 · strength 0.70
  6. Bei Sun · 7 shared papers, 2017–2023 · strength 0.70
  7. Le Li · 6 shared papers, 2018–2023 · strength 0.67
  8. Bei Sun · 4 shared papers, 2021–2026 · strength 0.64
  9. Chundong Cheng · 5 shared papers, 2019–2023 · strength 0.62
  10. Gang Wang · 4 shared papers, 2019–2026 · strength 0.61
  11. Yan Luo · 3 shared papers, 2023–2026 · strength 0.60
  12. Wenbo Yang · 4 shared papers, 2021–2023 · strength 0.56
  13. Yilong Li · 6 shared papers, 2017–2022 · strength 0.54
  14. Shangha Pan · 4 shared papers, 2017–2023 · strength 0.42
  15. Danxi Liu · 3 shared papers, 2022–2023 · strength 0.41
  16. Xinglong Geng · 3 shared papers, 2021–2023 · strength 0.41
  17. Le Li · 2 shared papers, 2023–2026 · strength 0.39
  18. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  19. Le Li · 3 shared papers, 2017–2021 · strength 0.28
  20. Tao Zhang · 2 shared papers, 2022–2023 · strength 0.27
  21. X W Bai · 1 shared paper, 2026 · strength 0.22
  22. Xinyuan Liu · 1 shared paper, 2026 · strength 0.22
  23. Yingmei Zhang · 1 shared paper, 2026 · strength 0.22
  24. Bo Sun · 1 shared paper, 2026 · strength 0.22
  25. Liwei Liu · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.